Avricore Health Inc. has successfully implemented its HealthTab™ point-of-care testing platform, screening over 3,500 patients across community pharmacies in North East and North Central London. This initiative, which includes a pilot program for HbA1c testing aimed at diabetes screening, achieved a monthly testing average that is ten times higher than previous efforts in Canada. The company has outlined its UK expansion strategy in a presentation titled “The Path Forward,” indicating a robust plan for scaling its operations within the NHS framework.

The significance of these findings is underscored by the identification of elevated cardiovascular risk in approximately 20% of patients screened in a lipid-testing cohort. This level of screening aligns with the growing emphasis on preventive healthcare and early intervention strategies. The program has garnered support from notable entities, including a $385,000 grant from the British Heart Foundation for a secondary-prevention pilot, highlighting the potential for HealthTab to integrate seamlessly into existing healthcare infrastructures and improve patient outcomes.

A key implication for the field is the anticipated shift in pharmacy practice as all newly qualified pharmacists in England will graduate as independent prescribers starting September 2026. This regulatory change is expected to further enhance the role of community pharmacies in public health, facilitating the broader adoption of point-of-care testing technologies like HealthTab. As Avricore aims to expand to over 500 active UK locations by mid-2027, the integration of comprehensive testing solutions could significantly streamline patient care pathways and accelerate the translation of diagnostic insights into actionable health interventions.

Source: globenewswire.com